Raymond James analyst Jayson Bedford has maintained an Outperform rating on Intuitive Surgical (NASDAQ: ISRG) while lowering the price target to $483. The reduction from the previous target of $577 reflects a revised valuation outlook for the stock. The Outperform stance suggests the stock is expected to outperform the broader market.

Rating and Price Target Details

The updated assessment provides a new benchmark for investors tracking the medical device company. The adjustment in the price target indicates a shift in the firm's expectations regarding the company's near-term performance.

Intuitive Surgical Inc shares fell to a fresh 52-week low on Friday, pressured by a string of Wall Street price-target cuts and concerns over slowing surgical procedure trends. The stock declined 13.14% to $349.45, caught in a pullback following the company's reaffirmation of its 2026 da Vinci procedure growth outlook. While the company maintained its full-year guidance, it flagged moderating U.S. procedure growth and insurance-related headwinds that weighed on investor sentiment.

Analysts Cut Price Forecasts

Piper Sandler analyst Adam Maeder maintained an Overweight rating but lowered the price target to $470 from $580, noting that U.S. procedure growth slowed by about 200 basis points sequentially. JPMorgan analyst Robbie Marcus maintained an Overweight rating but lowered the price target to $450 from $550. Mizuho analyst Anthony Petrone maintained a Neutral rating but lowered the price target to $400 from $500. Wells Fargo analyst Larry Biegelsen maintained an Overweight rating but lowered the price target to $487 from $654. TD Cowen analyst Mathew Blackman maintained a Buy rating but lowered the price target to $485 from $520. Evercore ISI analyst Vijay Kumar maintained an In Line rating but lowered the price target to $375 from $430. RBC Capital analyst Shagun Singh kept an Outperform rating while reducing the target to $575 from $600. Stifel lowered its target to $550 from $670, and Citigroup cut its target to $500 from $590. Bernstein analyst Lee Hambright maintained an Outperform rating but lowered the price target to $685 from $750. Leerink Partners analyst Mike Kratky maintained an Outperform rating but lowered the price target to $454 from $573. Baird analyst David Rescott maintained an Outperform rating but lowered the price target to $500 from $525. BTIG analyst Ryan Zimmerman maintained a Buy rating but lowered the price target to $469 from $512.

China Competition and International Headwinds

Chief Executive Officer David Rosa stated that the operating environment in China remains challenging due to lower tender activity, increased domestic robotic competition, and policy-driven pricing pressure. The company continues to navigate policy changes, including charge code revisions and China's 15th Five-Year Plan quota process. Rosa noted that the company is engaging with provincial governments on charge code policy and progressing through the green channel process for both SP and Da Vinci 5 platforms. In Japan, new reimbursement policies supporting robotic surgery took effect on June 1, expanding coverage for additional procedures.

U.S. Procedure Growth Slows

Chief Financial Officer Jamie Samath highlighted that the expiration of enhanced Affordable Care Act premium subsidies affected some patients and contributed to softer procedure growth. The company observed a moderation in procedure growth rate that started in Q1, particularly in benign procedures that can be deferred. U.S. da Vinci Bariatric cases continued to feel the impact of rising GLP-1 usage, declining high single digits during the quarter. William Blair noted that maintaining, rather than raising, guidance disappointed investors given the stock's premium valuation, though it maintained an Outperform rating citing the company's industry-leading earnings growth profile.